Showing results (1-10 of 20) with videos related to
Sort By:
Pageof 2
Diagnostics (Basel, Switzerland)|August 28, 2025
The Usefulness of Combined Digital Dermatoscopy and Ultrasound with Colour Doppler in the Diagnosis of Skin LesionsCésar Martins, Helena Pópulo, Paula SoaresInternational Journal of Molecular Sciences|March 13, 2012
The mTOR signalling pathway in human cancerHelena Pópulo, José Manuel Lopes, Paula SoaresExpert Opinion on Therapeutic Targets|May 25, 2012
Insights into melanoma: targeting the mTOR pathway for therapeuticsHelena Pópulo, Paula Soares, José Manuel LopesImmunotargets and Therapy|June 21, 2018
Melanoma treatment in reviewBeatriz Domingues, José Manuel Lopes, Paula Soares, et al.The British Journal of Ophthalmology|September 1, 2010
Analysis of GNAQ mutations, proliferation and MAPK pathway activation in uveal melanomasHelena Pópulo, João Vinagre, José Manuel Lopes, et al.The Biochemical Journal|June 7, 2002
Disruption of iron-sulphur cluster N2 from NADH: ubiquinone oxidoreductase by site-directed mutagenesisMargarida Duarte, Helena Pópulo, Arnaldo Videira, et al.Journal of Experimental Pharmacology|June 3, 2021
Combinatorial Therapies to Overcome BRAF/MEK Inhibitors Resistance in Melanoma Cells: An in vitro StudyHelena Pópulo, Beatriz Domingues, Cristina Sampaio, et al.Melanoma Research|February 23, 2010
Evaluation of the mTOR pathway in ocular (uvea and conjunctiva) melanomaHelena Pópulo, Paula Soares, Ana Sofia Rocha, et al.Expert Opinion on Therapeutic Targets|May 16, 2015
Overexpression of pyruvate dehydrogenase kinase supports dichloroacetate as a candidate for cutaneous melanoma therapyHelena Pópulo, Regina Caldas, José Manuel Lopes, et al.Plos One|June 30, 2017
SDHD promoter mutations are rare events in cutaneous melanomas but SDHD protein expression is downregulated in advanced cutaneous melanomaHelena Pópulo, Rui Batista, Cristina Sampaio, et al.Pageof 2